Every 424B that Corvus Pharmaceu (CRVS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CRVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRVS filings page.
Registers up to $200,000,000 of common stock for sale in an amended at-the-market program. Corvus Pharmaceuticals amended its open market sales agreement with Jefferies to increase the maximum aggregate offering price from $100,000,000 to $200,000,000, with Jefferies serving as sales agent. The company has not sold shares under the prior agreement and suspended the prior program effective January 20, 2026. Sales, if any, will be made from time to time on the Nasdaq Global Market under an at the market plan; Jefferies may receive up to 3.0% of gross proceeds as compensation. The prospectus cites a March 11, 2026 last reported sale price of $16.90 and states shares outstanding of 74,696,629 as of December 31, 2025.
Corvus Pharmaceuticals, Inc. is offering 7,900,677 shares of common stock at $22.15 per share in an underwritten public offering on the Nasdaq Global Market. Underwriters also have a 30‑day option to buy up to 1,185,101 additional shares, implying gross proceeds of about $174.999,995.55 and underwriting discounts and commissions of $10,499,999.73, before expenses.
The company expects net proceeds of approximately $163.6 million, or $188.3 million if the option is fully exercised, and plans to use the cash mainly for working capital and research and development, including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma trials, plus sales, marketing and administrative expenses. Together with existing cash, cash equivalents and marketable securities, Corvus expects to fund operations into the first quarter of 2028.
Corvus recently reported positive Phase 1 cohort 4 data for soquelitinib in moderate to severe atopic dermatitis, showing a 72% mean reduction in EASI at day 56 versus 40% on placebo and higher EASI 75 and IGA 0/1 response rates, including in patients previously treated with systemic therapies. As of December 31, 2025, it preliminarily estimates cash, cash equivalents and marketable securities of about $56.7 million and has suspended its $100 million at‑the‑market program with Jefferies after selling no shares.
Corvus Pharmaceuticals is launching a $150 million primary offering of common stock and pre-funded warrants, plus an underwriters’ option for up to an additional $22.5 million of common stock. The pre-funded warrants are priced at the share offering price minus $0.0001 and are exercisable at $0.0001 per share, subject to ownership caps, and this prospectus also covers the shares issuable upon their exercise. Corvus reports positive Phase 1 data for soquelitinib in moderate to severe atopic dermatitis, with a 72% mean EASI reduction at day 56 versus 40% for placebo in cohort 4 and favorable safety. The company had approximately $56.7 million in cash, cash equivalents and marketable securities as of December 31, 2025 on a preliminary basis, and expects existing cash plus offering proceeds to fund operations into the first quarter of 2028, although it has disclosed substantial doubt about its ability to continue as a going concern without additional capital.